<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569032</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-032</org_study_id>
    <nct_id>NCT04569032</nct_id>
  </id_info>
  <brief_title>A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression</brief_title>
  <official_title>A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for&#xD;
      people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out&#xD;
      what side effects occur when brentuximab vedotin and CHP are used together. A side effect is&#xD;
      anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three&#xD;
      drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat&#xD;
      certain types of PTCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) per blinded independent central review (BICR) using Revised Response Criteria for Malignant Lymphoma criteria (Cheson 2007)</measure>
    <time_frame>From start of study treatment up to approximately 7 months</time_frame>
    <description>ORR is defined as the proportion of participants with complete response (CR) or partial response (PR) at the completion of study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate per BICR</measure>
    <time_frame>From start of study treatment up to approximately 7 months</time_frame>
    <description>CR rate is defined as the proportion of participants with CR following the completion of study treatment using Revised Response Criteria of Malignant Lymphoma (Cheson 2007).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per BICR</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time from start of treatment to the first documented disease progression or death from any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time from first dose to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per BICR</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Time from first occurrence of an objective response to the date of disease progression or death from any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per BICR per modified Lugano criteria (Cheson 2014)</measure>
    <time_frame>From start of study treatment up to approximately 7 months</time_frame>
    <description>ORR is defined as the proportion of participants with CR or PR at the completion of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From start of study treatment up to approximately 7 months</time_frame>
    <description>An adverse event is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>From start of study treatment up to approximately 7 months</time_frame>
    <description>To be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD30-negative Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD30 expression level &lt; 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD30-positive Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD30 expression level ≥1% to &lt; 10%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle</description>
    <arm_group_label>CD30-negative Cohort</arm_group_label>
    <arm_group_label>CD30-positive Cohort</arm_group_label>
    <other_name>ADCETRIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>750 mg/m^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle</description>
    <arm_group_label>CD30-negative Cohort</arm_group_label>
    <arm_group_label>CD30-positive Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>50 mg/m^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle</description>
    <arm_group_label>CD30-negative Cohort</arm_group_label>
    <arm_group_label>CD30-positive Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>100 mg daily administered orally on Days 1-5 of each cycle</description>
    <arm_group_label>CD30-negative Cohort</arm_group_label>
    <arm_group_label>CD30-positive Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Newly diagnosed PTCL, excluding systemic anaplastic large cell lymphoma (sALCL), per&#xD;
             the Revised European-American Lymphoma World Health Organization (WHO) 2016&#xD;
             classification&#xD;
&#xD;
          -  The following non-sALCL PTCL subtypes are eligible:&#xD;
&#xD;
               -  PTCL - not otherwise specified (PTCL-NOS)&#xD;
&#xD;
               -  Angioimmunoblastic T-cell lymphoma (AITL)&#xD;
&#xD;
               -  Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be&#xD;
                  positive for human T cell leukemia virus 1)&#xD;
&#xD;
               -  Enteropathy-associated T-cell lymphoma (EATL)&#xD;
&#xD;
               -  Hepatosplenic T-cell lymphoma&#xD;
&#xD;
               -  Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITCL)&#xD;
&#xD;
               -  Indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI)&#xD;
                  tract&#xD;
&#xD;
               -  Follicular T-cell lymphoma&#xD;
&#xD;
               -  Nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype&#xD;
&#xD;
          -  CD30 expression &lt;10% by local assessment in tumor containing lymph node or other&#xD;
             extranodal soft tissue biopsy&#xD;
&#xD;
          -  Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm&#xD;
             by CT, as assessed by the site radiologist&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to&#xD;
             2&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Current diagnosis of any of the following:&#xD;
&#xD;
               -  sALCL&#xD;
&#xD;
               -  Primary cutaneous T-cell lymphoproliferative disorders and lymphomas&#xD;
&#xD;
               -  Mycosis fungoides (MF), including transformed MF&#xD;
&#xD;
          -  History of another primary invasive cancer, hematologic malignancy, or myelodysplastic&#xD;
             syndrome that has not been in remission for at least 3 years. Exceptions are&#xD;
             malignancies with a negligible risk of metastasis or death (e.g., 5-year OS ≥90%),&#xD;
             such as carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized&#xD;
             prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.&#xD;
&#xD;
          -  History of progressive multifocal leukoencephalopathy (PML).&#xD;
&#xD;
          -  Cerebral/meningeal disease related to the underlying malignancy.&#xD;
&#xD;
          -  Prior treatment with brentuximab vedotin or doxorubicin.&#xD;
&#xD;
          -  Baseline peripheral neuropathy Grade 2 or higher (per the NCI CTCAE, Version 4.03) or&#xD;
             subjects with the demyelinating form of Charcot-Marie-Tooth syndrome.&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 45% or symptomatic cardiac disease&#xD;
             (including symptomatic ventricular dysfunction, symptomatic coronary artery disease,&#xD;
             and symptomatic arrhythmias), or myocardial infarction within the past 6 months, or&#xD;
             previous treatment with complete cumulative dose of &gt;300 mg/m2 of doxorubicin.&#xD;
&#xD;
          -  Any uncontrolled Grade 3 or higher (per the National Cancer Institute's Common&#xD;
             Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03) viral, bacterial, or&#xD;
             fungal infection within 2 weeks prior to the first dose of study drug. Routine&#xD;
             antimicrobial prophylaxis is permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Knowles, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany D Hill</last_name>
      <phone>205-996-8023</phone>
    </contact>
    <investigator>
      <last_name>Gaurav Goyal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center / Blood and Marrow Transplant Program</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariel Rojas</last_name>
      <phone>650-723-0530</phone>
      <email>mlrojas@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjana Advani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Graham</last_name>
      <phone>281-863-6592</phone>
      <email>amber.graham@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>John M Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Wood</last_name>
      <phone>202-660-5772</phone>
      <email>Bwood25@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Leena Rahmat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists / Advocate Lutheran General Hospital</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Graham</last_name>
      <phone>281-863-6592</phone>
      <email>Amber.Graham@McKesson.com</email>
    </contact>
    <investigator>
      <last_name>Leonard Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Hospital and Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Tatje</last_name>
      <phone>504-988-2987</phone>
    </contact>
    <investigator>
      <last_name>Nakhle Saba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Rich</last_name>
      <phone>504-842-2466</phone>
      <email>Meghan.rich@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Laura E Finn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Michigan Cancer Answer Line</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Ryan Wilcox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Maccaro</last_name>
      <phone>646-227-3010</phone>
    </contact>
    <investigator>
      <last_name>Steven Horwitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, The</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spela Pirc</last_name>
      <phone>216-444-9138</phone>
    </contact>
    <investigator>
      <last_name>Deepa Jagadeesh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Graham</last_name>
      <phone>281-863-6592</phone>
      <email>amber.graham@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Islas-Ohlmayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Parkey</last_name>
      <phone>865-305-6194</phone>
      <email>jparkey@utmck.edu</email>
    </contact>
    <investigator>
      <last_name>Radhakrishnan Ramchandren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Graham</last_name>
      <phone>281-863-6592</phone>
      <email>amber.graham@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Praveen K Tumula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Graham</last_name>
      <phone>281-863-6592</phone>
      <email>amber.graham@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Jason M Melear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth 12th Avenue</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Graham</last_name>
      <phone>281-863-6592</phone>
      <email>amber.graham@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Harris V Naina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathrine Paras</last_name>
      <phone>713-745-4367</phone>
    </contact>
    <investigator>
      <last_name>Swaminathan P Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Graham</last_name>
      <phone>281-863-6592</phone>
      <email>amber.graham@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Habte A Yimer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Biamonte</last_name>
      <phone>804-628-1896</phone>
    </contact>
    <investigator>
      <last_name>Victor Y Yazbeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates - Virginia Beach</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Graham</last_name>
      <phone>281-863-6592</phone>
      <email>amber.graham@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Celeste A Bremer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendee, Site de La Roche-sur-Yon, Les Oudairies</name>
      <address>
        <city>Cedex 9</city>
        <state>Other</state>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephane Vigouroux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <state>Other</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvain Carras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <state>Other</state>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernard Drenou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <state>Other</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kamal Krimo Bouabdallah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <state>Other</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuel Bachy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel / Centre Regional de Lutte Contre le Cancer</name>
      <address>
        <city>Rouen</city>
        <state>Other</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Camus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna - IRCCS</name>
      <address>
        <city>Bologna</city>
        <state>Other</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pier Luigi Zinzani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <state>Other</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabio Benedetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Paul</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Briones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala D'Oncologia Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Domingo Domenech</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Angel Canales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>Other</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kate Cwynarski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>Other</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tim Illidge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD30-positive</keyword>
  <keyword>CD30-negative</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

